Matthew Hart

Matthew Hart's work experience begins with their current role as a Scientist at RareCyte, Inc. Their primary work involves characterizing gene expression signatures from ultra rare circulating placental cells in order to identify indicators of stillbirth or other complications during pregnancy.

Prior to their current role, Matthew worked as a Staff Scientist at Fred Hutch from 2019 to 2023. Here, they studied CD4 and CD8 T cell development and lineage specification, with a focus on optimizing memory capacity and effectorness for CAR T applications. Their work incorporated various immunological techniques and emerging areas of research and technology.

Before Fred Hutch, Matthew worked as a Senior Fellow (Post Doc) at the University of Washington from 2013 to 2019. Their research focused on pre-B cell leukemia, specifically exploring the potential of latent gene paralogs to rescue loss of function mutations in the PAX5 developmental transcription factor.

Matthew's work experience also includes a role as a Graduate Research Assistant at the University of Arizona from 2006 to 2013, where they studied EGFR/ERBB receptor trafficking and activity in breast and pancreatic cancer.

Additionally, they worked as a Research Associate at the Allen Institute for Brain Science from 2005 to 2006 and as an Intern at Stanford University in 2004.

Matthew Hart completed their Bachelor of Science (B.S.) degree in Molecular Biology from the University of Washington in 2004. Matthew then pursued their Ph.D. in Genetics from the University of Arizona, completing it in 2013. Following this, they engaged in postdoctoral study at the University of Washington from 2013 to 2019, focusing on Cancer and Molecular Biology Genetics.